Results 241 to 250 of about 104,915 (286)
Some of the next articles are maybe not open access.
Investigating beneficial drug reactions
BMJ, 2012Abstract OBJECTIVES The aim of this study was to explore the full range of tricuspid valve regurgitation velocity (TRV) at rest and with exercise in disease free individuals. Additionally we examined the relationship of stroke volume (SV), cardiac output (CO) and TRV to exercise capacity. BACKGROUND Doppler evaluation of TRV can be used to estimate
Jim, Parle, Nick, Ross, June, Jones
openaire +2 more sources
Investigational drug labeling variability
Clinical Trials, 2019Background/aims In comparison with commercial drugs, there are few regulations concerning the labeling of investigational drugs. This leads to variability in their content and layout. This increases the risk of errors during storage, validation, compounding, dispensing and administration.
Amélie Duhamel +4 more
openaire +2 more sources
Investigational drugs for hyperuricemia
Expert Opinion on Investigational Drugs, 2015The unmet need and the growing prevalence of hyperuricemia and its complications worldwide have pushed investigators to identify new agents to manage hyperuricemia.This review discusses the drugs in preclinical and early clinical trials for hyperuricemia, their mechanisms of action and available results. This article reviews a total of 10 novel agents:
Hania, Shahid, Jasvinder A, Singh
openaire +2 more sources
Sarcoidosis: Drugs under Investigation
Seminars in Respiratory and Critical Care Medicine, 2017AbstractEtiology of sarcoidosis is still elusive, yet there has been considerable progress in various areas of basic and clinical research. In this review, we focus on ongoing or recently completed clinical–pharmacological studies in patients with sarcoidosis.
Schupp, Jonas Christian +3 more
openaire +3 more sources
Investigational drugs for pruritus
Expert Opinion on Investigational Drugs, 2013Chronic pruritus (CP), defined as itch lasting for > 6 weeks, is a burdensome symptom of several different diseases, dermatological and systemic, with a high negative impact on the quality of life of patients. Given the manifold aetiologies of CP, therapy is often difficult.
Heike, Benecke +2 more
openaire +2 more sources
American Journal of Health-System Pharmacy, 1967
Clifton J. Latiolais, Roger Anderson
+4 more sources
Clifton J. Latiolais, Roger Anderson
+4 more sources
Investigational drugs for endometriosis
Expert Opinion on Investigational Drugs, 2006Endometriosis is an enigmatic disease found in as many as 30% of reproductive age women. The symptoms for women who suffer from this malady vary but may include subfertility or chronic pelvic pain. Because endometriosis lesions rely on estradiol for growth, most of the existing drug regimens work by creating hypoestrogenism.
Richard O, Chlouber +2 more
openaire +2 more sources
Investigational drugs for onychomycosis
Expert Opinion on Investigational Drugs, 2013Onychomycosis is the fungal infection of the nail plate by dermatophytes, yeasts and nondermatophyte molds. The treatment of onychomycosis poses many challenges due to low initial cure rates and a high rate of relapse and recurrence. Oral therapy is limited by adverse events and drug-drug interactions, whereas topical therapy has limited penetrance ...
Aditya K, Gupta, Fiona C, Simpson
openaire +2 more sources
American Journal of Health-System Pharmacy, 1969
C J, Latiolais, J A, Visconti
openaire +3 more sources
C J, Latiolais, J A, Visconti
openaire +3 more sources
Investigating drug induced alopecia
Nursing Standard, 1993The propensity of cytotoxic drugs to cause alopecia is well known, but nurses are perhaps less aware of the capacity of other drug groups to cause this unwanted side-effect. Increasing nurses' awareness of the actions of these drugs will enable the association between alopecia and toxicity to be recognised at an early stage, before the distressing ...
openaire +2 more sources